-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Endoscopic mucosal resection (ER) is the best treatment for esophageal squamous cell carcinomas (ESCCs) whose lesions are confined to the esophageal epithelium.
Endoscopic mucosal resection (ER) is the best treatment for esophageal squamous cell carcinomas (ESCCs) whose lesions are confined to the esophageal epithelium.
Researchers retrospectively collected pT1a-MM/pT1b-SM ESCC patients who received ER in 21 medical institutions in Japan from 2006 to 2017, and then compared the prognosis of patients who received and did not receive additional treatment.
A total of 593 patients were enrolled in this study, of which 38 had cancer recurrence and metastasis.
Figure: The relationship between cancer recurrence and depth of invasion
Patients with esophageal cancer whose tumor cells infiltrate into the muscularis mucosa (pT1a-MM) or submucosa (pT1b-SM) receive ER and need to receive additional treatment to reduce postoperative cancer recurrence.
Patients with esophageal cancer whose tumor cells infiltrate into the muscularis mucosa (pT1a-MM) or submucosa (pT1b-SM) receive ER and need to receive additional treatment to reduce postoperative cancer recurrence.
Original source:
Waku Hatta.
springer.
com/article/10.
1007/s00535-021-01787-y" target="_blank" rel="noopener">Risk of metastatic recurrence after endoscopic resection for esophageal squamous cell carcinoma invading into the muscularis mucosa or submucosa: a multicenter retrospective study.
Leave a message here